Posts by: Alice Melão

News

Trovagene’s investigational oral therapy onvansertib may help overcome resistance to Zytiga (abiraterone acetate) in men with metastatic castration-resistant prostate cancer (mCRPC), updated Phase 2 data continue to suggest. The trial (NCT03414034) ... Read more

November 14, 2019November 14, 2019

Enrollment Completed for Phase 3 Trial Testing Provenge in Prostate Cancer Patients on Active Surveillance

News

Dendreon Pharmaceuticals has completed patient enrollment ahead of schedule in an ongoing Phase 3 trial assessing the safety and efficacy of its immunotherapy Provenge (sipuleucel-T) for men with early-stage prostate ... Read more

November 13, 2019

Phase 1 DRGT-45 Trial Doses First Patient With New Oral Formulation of Abiraterone Acetate

News

A Phase 1 clinical trial testing DRGT-45 — a new oral formulation of abiraterone acetate — in men with prostate cancer has dosed its first participant, the treatment’s developer, Druggability ... Read more

October 14, 2019October 14, 2019

Liproca Depot Shows Promise for Treatment of Early-Stage Prostate Cancer

News

A new injectable flutamide formulation called Liproca Depot is safe, well-tolerated and shows sustained efficacy in untreated men with localized prostate cancer, according to early results of a Phase 2b clinical ... Read more

September 9, 2019September 24, 2019

Provenge Extends Survival of mCRPC Patients By Up to 4 Years, Data Show

News

Treatment with the immunotherapy Provenge (sipuleucel-T) in a real-world setting is showing similar safety and efficacy in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC) as in ... Read more

July 25, 2019

PyL Imaging Agent Ably Detects Lesions Outside the Prostate, Phase 2/3 Trial Shows

News

PyL, a new imaging agent for positron emission topography (PET) scans, can accurately detect prostate cancer lesions outside the prostate, whether in nearby lymph nodes or in distant locations, clinical ... Read more

July 22, 2019August 26, 2019

MSN Labs to Launch Generic Version of Zytiga in U.S. Following FDA Approval

News

MSN Labs, the parent company of Novadoz Pharmaceuticals, is launching a generic version of Janssen Pharmaceuticals’ approved therapy Zytiga (abiraterone acetate) in the U.S. market. Following its approval by the ... Read more

July 15, 2019

Veyonda-LuPSMA Radiotherapy Safe, Well-tolerated in Advanced PC, Early Trial Results Show

News

A combination of Noxopharm’s radiation sensitizer Veyonda (idronoxil) and 177LuPSMA-617 — a kind of targeted radiation therapy — is safe and well-tolerated, and appears to have a high efficacy in ... Read more

June 20, 2019

Investigational AMG 212 Shows Anti-cancer Activity in Advanced mCRPC in Phase 1 Trial

News

Amgen’s investigational therapy AMG 212 (pasotuxizumab) is safe, and showing therapeutic activity against metastatic castration-resistant prostate cancer (mCRPC) in a Phase 1 clinical trial, data show. This is the first ... Read more

May 9, 2019

Single Dose of Brachytherapy Safe, Effective for Localized PC, Study Shows

News

Men with low-risk prostate cancer can safely receive a single high dose of brachytherapy — a type of radiation therapy delivered directly into the tumor within a few minutes — ... Read more